RxDoctor Payments Data

Supreeya Swarup, DO

Interventional Cardiology · Santa Rosa, CANPI 1750679916

Payments from drug & device makers

$9,221in general payments, 2019–2025

Across 184 payments — averaging $50.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$3K
  • Abiomed$2K
  • Cardiovascular Systems Inc.$714
  • E.r. Squibb & Sons, L.L.C.$192
  • Inari Medical, Inc.$137
  • plus $464 from 11 others

What the payments were for

  • Travel & lodging$4,54249%
  • Food & beverage$4,67951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,221 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$165,003
Medicare patients
1,205
Services billed
3,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$131,197
EntrestoSacubitril/Valsartan42$57,621
JardianceEmpagliflozin49$53,735
Repatha SureclickEvolocumab25$20,730
XareltoRivaroxaban14$16,982
BrilintaTicagrelor13$11,784
Hydralazine Hcl126$2,513
Atorvastatin Calcium109$1,544
Metoprolol Succinate118$1,282
Amlodipine Besylate178$1,023
Rosuvastatin Calcium79$883
Carvedilol130$842
Losartan Potassium76$700
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$544
Ezetimibe12$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$32$53,73549 claims
Johnson & JohnsonXarelto$20$16,98214 claims
AstraZenecaBrilinta$14$11,78413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →